{"id":"comirnaty-vaccine","safety":{"commonSideEffects":[{"rate":"70–90","effect":"Injection site pain"},{"rate":"60–70","effect":"Fatigue"},{"rate":"50–60","effect":"Headache"},{"rate":"40–60","effect":"Myalgia"},{"rate":"15–30","effect":"Fever"},{"rate":"30–40","effect":"Chills"},{"rate":"20–30","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine delivers lipid nanoparticle-encapsulated messenger RNA encoding the full-length spike protein of SARS-CoV-2. Upon intramuscular injection, the mRNA is translated by host ribosomes to produce spike protein antigen, which activates both CD8+ T-cell and B-cell mediated immunity. This dual immune response generates neutralizing antibodies and cellular immunity to protect against severe COVID-19 disease.","oneSentence":"Comirnaty is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:47.163Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 disease caused by SARS-CoV-2"}]},"trialDetails":[{"nctId":"NCT05212610","phase":"PHASE4","title":"Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-03-21","conditions":"COVID-19, Corona Virus Infection","enrollment":137},{"nctId":"NCT05265065","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-27","conditions":"COVID-19","enrollment":601},{"nctId":"NCT05283902","phase":"","title":"Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly","status":"COMPLETED","sponsor":"Federal University of Espirito Santo","startDate":"2022-03-19","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine-Preventable Diseases","enrollment":260},{"nctId":"NCT06181292","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2023-11-15","conditions":"SARS-CoV2 Infection","enrollment":913},{"nctId":"NCT07280858","phase":"PHASE1, PHASE2","title":"A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.","status":"RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2026-01-28","conditions":"Healthy Participants, Sarbecovirus","enrollment":368},{"nctId":"NCT07390968","phase":"PHASE2","title":"Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-09-01","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":56},{"nctId":"NCT05951920","phase":"NA","title":"Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-05","conditions":"COVID-19","enrollment":12},{"nctId":"NCT05077254","phase":"PHASE2","title":"COVID Protection After Transplant-Immunosuppression Reduction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-06","conditions":"Kidney Transplant Recipients, Liver Transplant Recipients","enrollment":48},{"nctId":"NCT04760704","phase":"","title":"Covid-19 Vaccine Response in Elderly Subjects","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2021-02-18","conditions":"Covid19 Vaccine","enrollment":264},{"nctId":"NCT06821126","phase":"PHASE1, PHASE2","title":"Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-05-09","conditions":"Healthy","enrollment":238},{"nctId":"NCT04780659","phase":"PHASE4","title":"COVID-19 Vaccination of Immunodeficient Persons (COVAXID)","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2021-02-23","conditions":"Covid19","enrollment":539},{"nctId":"NCT05032976","phase":"","title":"Korea Comirnaty Post-marketing Surveillance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-03-18","conditions":"COVID-19, Vaccines, Adverse Effects","enrollment":12000},{"nctId":"NCT06742281","phase":"PHASE2","title":"A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"CyanVac LLC","startDate":"2024-12-05","conditions":"COVID-19","enrollment":432},{"nctId":"NCT06672055","phase":"PHASE2","title":"A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaxart","startDate":"2024-10-08","conditions":"SARS-CoV2, COVID-19","enrollment":10400},{"nctId":"NCT05556720","phase":"PHASE3","title":"Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2022-12-01","conditions":"HIV, Organ Transplantation, Lymphoma, Non-Hodgkin","enrollment":960},{"nctId":"NCT05295290","phase":"PHASE4","title":"A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-11-21","conditions":"Myocarditis","enrollment":300},{"nctId":"NCT06452654","phase":"PHASE4","title":"Anti-viral Action Against Type 1 Diabetes Autoimmunity","status":"RECRUITING","sponsor":"Technical University of Munich","startDate":"2024-05-08","conditions":"Diabetes Mellitus, Type 1","enrollment":2252},{"nctId":"NCT07134725","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a Chimeric Recombinant Covid19 Vaccine SpiN-Tec MCTI UFMG","status":"COMPLETED","sponsor":"Federal University of Minas Gerais","startDate":"2022-11-23","conditions":"COVID - 19","enrollment":432},{"nctId":"NCT04969263","phase":"PHASE2","title":"COVID-19 Protection After Transplant Pilot Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-10","conditions":"Kidney Transplant Recipients","enrollment":81},{"nctId":"NCT06130410","phase":"","title":"Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-03-06","conditions":"SARS-CoV-2, COVID-19","enrollment":25},{"nctId":"NCT05621239","phase":"","title":"A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-03-15","conditions":"COVID-19","enrollment":260},{"nctId":"NCT05160766","phase":"PHASE2","title":"Assessing Immune Response of Different COVID-19 Vaccines in Older Adults","status":"COMPLETED","sponsor":"Oliver Cornely, MD","startDate":"2021-11-08","conditions":"Prevention of COVID-19","enrollment":323},{"nctId":"NCT05904054","phase":"PHASE2","title":"Immunogenicity and Safety Study of SARS-CoV-2 DNA Vaccine (ICCOV)","status":"COMPLETED","sponsor":"Immuno Cure 3 Limited","startDate":"2023-06-15","conditions":"COVID-19","enrollment":31},{"nctId":"NCT06919796","phase":"PHASE2","title":"mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes","status":"NOT_YET_RECRUITING","sponsor":"PharmaJet, Inc.","startDate":"2025-05-01","conditions":"Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2","enrollment":40},{"nctId":"NCT05605470","phase":"PHASE2","title":"Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults","status":"COMPLETED","sponsor":"Technovalia, Pty Ltd","startDate":"2023-01-19","conditions":"COVID-19, SARS CoV 2 Infection","enrollment":150},{"nctId":"NCT05110911","phase":"","title":"Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-04-02","conditions":"Influenza, Human, SARS-CoV-2 Infection","enrollment":1500},{"nctId":"NCT04894435","phase":"PHASE2","title":"Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2021-05-20","conditions":"COVID-19","enrollment":669},{"nctId":"NCT05329220","phase":"PHASE3","title":"ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2022-08-30","conditions":"COVID-19 Disease","enrollment":4205},{"nctId":"NCT05228730","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).","status":"TERMINATED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-02","conditions":"COVID-19","enrollment":13},{"nctId":"NCT05599555","phase":"","title":"Community-based Sero-epidemiological Study of COVID-19","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2022-04-28","conditions":"COVID-19","enrollment":9600},{"nctId":"NCT04815031","phase":"","title":"Drug Use Investigation of COMIRNATY Intramuscular Injection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-03-20","conditions":"COVID-19","enrollment":14570},{"nctId":"NCT05993325","phase":"PHASE3","title":"Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cellid Co., Ltd.","startDate":"2023-11-27","conditions":"COVID-19, Vaccines","enrollment":4000},{"nctId":"NCT05028257","phase":"PHASE3","title":"Allergy and COVID-19 Vaccines","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-15","conditions":"Anaphylactic Reaction, Vaccine Reaction","enrollment":117},{"nctId":"NCT05858450","phase":"","title":"This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-05-05","conditions":"Influenza, Human, COVID-19","enrollment":3442996},{"nctId":"NCT04949490","phase":"PHASE2","title":"A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2021-07-26","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":137},{"nctId":"NCT05515042","phase":"PHASE2","title":"Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2022-07-25","conditions":"COVID-19","enrollment":694},{"nctId":"NCT04969601","phase":"PHASE1, PHASE2","title":"Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-29","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":76},{"nctId":"NCT04880447","phase":"","title":"Special Investigation of COMIRNATY in the Population With Underlying Diseases","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-26","conditions":"COVID-19","enrollment":1075},{"nctId":"NCT04792567","phase":"PHASE4","title":"Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-04-19","conditions":"Secondary Progressive Multiple Sclerosis","enrollment":41},{"nctId":"NCT05863429","phase":"","title":"Observational National Vaccine Study","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2022-05-18","conditions":"COVID-19 Infection","enrollment":200},{"nctId":"NCT04760132","phase":"PHASE4","title":"National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE)","status":"COMPLETED","sponsor":"Jens D Lundgren, MD","startDate":"2021-02-08","conditions":"SARS-CoV Infection","enrollment":7600},{"nctId":"NCT05977127","phase":"PHASE2","title":"Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2023-09-26","conditions":"Vaccination; Infection, COVID-19","enrollment":48},{"nctId":"NCT05406908","phase":"PHASE4","title":"Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2022-06-15","conditions":"Bullous Dermatoses, Psoriasis, COVID-19 Vaccines","enrollment":109},{"nctId":"NCT05387317","phase":"PHASE3","title":"Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2024-04","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05781191","phase":"","title":"Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-11-13","conditions":"Influenza, COVID-19","enrollment":8231},{"nctId":"NCT05543356","phase":"PHASE3","title":"COVID-19 Fourth Dose Study in Australia","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05924685","phase":"PHASE4","title":"PREPARE-iVAC Trial","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2023-08-22","conditions":"COVID-19 Vaccines, Varicella Zoster Vaccine, Vaccine Response","enrollment":110},{"nctId":"NCT05084989","phase":"PHASE2","title":"Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)","status":"COMPLETED","sponsor":"Jiangsu Rec-Biotechnology Co., Ltd.","startDate":"2022-01-31","conditions":"COVID-19","enrollment":948},{"nctId":"NCT05239975","phase":"PHASE2","title":"A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine","status":"WITHDRAWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-04-25","conditions":"COVID-19, SARS-CoV2 Infection","enrollment":""},{"nctId":"NCT04954287","phase":"PHASE1","title":"Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents","status":"COMPLETED","sponsor":"CyanVac LLC","startDate":"2021-08-06","conditions":"Covid19","enrollment":72},{"nctId":"NCT04805125","phase":"PHASE3","title":"Immunocompromised Swiss Cohorts Based Trial Platform","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-04-19","conditions":"Immunocompromised Patients","enrollment":610},{"nctId":"NCT05075538","phase":"PHASE4","title":"COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2021-12-01","conditions":"Cancer","enrollment":152},{"nctId":"NCT05057182","phase":"PHASE4","title":"Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-10-18","conditions":"COVID 19 Vaccine","enrollment":300},{"nctId":"NCT05057169","phase":"PHASE4","title":"Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-11-18","conditions":"COVID-19 Vaccination","enrollment":400},{"nctId":"NCT05930730","phase":"PHASE2","title":"Immunogenicity and Safety of Comvigen (Bivalent) Vaccine","status":"UNKNOWN","sponsor":"Chulalongkorn University","startDate":"2023-10-09","conditions":"Safety of a Single Dose of COMVIGEN Vaccine, Reactogenicity of a Single Dose of COMVIGEN Vaccine, Immunogenicity of a Single Dose of COMVIGEN Vaccine","enrollment":450},{"nctId":"NCT04977479","phase":"PHASE2","title":"The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-08","conditions":"Systemic Allergic Reaction","enrollment":20},{"nctId":"NCT04826770","phase":"","title":"Adaptive Immune Response to COVID-19 Vaccination","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2021-01-06","conditions":"SARS-CoV-2 Vaccination","enrollment":70},{"nctId":"NCT05188677","phase":"PHASE3","title":"Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2022-06-13","conditions":"COVID-19","enrollment":1831},{"nctId":"NCT05602961","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster","status":"WITHDRAWN","sponsor":"GreenLight Biosciences, Inc.","startDate":"2023-02-21","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05405283","phase":"PHASE3","title":"Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-06-08","conditions":"COVID-19 Vaccines","enrollment":189},{"nctId":"NCT05749926","phase":"PHASE3","title":"Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-05-16","conditions":"Vaccine Reaction, COVID-19","enrollment":248},{"nctId":"NCT05516459","phase":"","title":"Prospective Monitoring of BNT162b2 Second Vaccination Booster Effects in Health Care Workers (HCW)","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"2022-01-06","conditions":"Coronavirus Infections","enrollment":635},{"nctId":"NCT05490108","phase":"PHASE1, PHASE2","title":"Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.","status":"UNKNOWN","sponsor":"Shanghai Zerun Biotechnology Co.,Ltd","startDate":"2022-06-02","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":60},{"nctId":"NCT05323461","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-05-30","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":1800},{"nctId":"NCT04852861","phase":"PHASE4","title":"COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine","status":"COMPLETED","sponsor":"Sciensano","startDate":"2021-05-10","conditions":"Covid19","enrollment":145},{"nctId":"NCT05305573","phase":"PHASE2","title":"Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2022-03-25","conditions":"COVID-19, SARS-CoV-2 Acute Respiratory Disease","enrollment":26},{"nctId":"NCT05168709","phase":"PHASE4","title":"Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-01-20","conditions":"COVID-19, Vaccine Reaction, Immunization; Infection","enrollment":51},{"nctId":"NCT05208983","phase":"","title":"SafeTy and Efficacy of Preventative CoVID Vaccines","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-05-06","conditions":"COVID-19 Virus Infection, Vaccine Response","enrollment":1286},{"nctId":"NCT05394012","phase":"PHASE1","title":"A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19","status":"UNKNOWN","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2022-12","conditions":"COVID-19","enrollment":120},{"nctId":"NCT05618548","phase":"","title":"Vaccination Against COVID-19 in Pregnant and Lactating Women in Belgium","status":"UNKNOWN","sponsor":"Universiteit Antwerpen","startDate":"2021-03-01","conditions":"Covid19","enrollment":110},{"nctId":"NCT05083065","phase":"","title":"Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine","status":"COMPLETED","sponsor":"Università degli Studi dell'Insubria","startDate":"2021-09-10","conditions":"COVID-19, Vaccine, Menstrual Irregularity","enrollment":369},{"nctId":"NCT05542693","phase":"PHASE2","title":"Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine","status":"UNKNOWN","sponsor":"Azidus Brasil","startDate":"2023-01","conditions":"COVID-19, COVID-19 Vaccine","enrollment":300},{"nctId":"NCT05534048","phase":"PHASE3","title":"Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older","status":"UNKNOWN","sponsor":"Everest Medicines (Singapore) Pte. Ltd.","startDate":"2023-02-03","conditions":"SARS-CoV-2 Infection","enrollment":3800},{"nctId":"NCT05150496","phase":"PHASE2","title":"Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey","status":"SUSPENDED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-12-15","conditions":"COVID-19","enrollment":640},{"nctId":"NCT04799808","phase":"","title":"Saxon SARS-CoV-2 Infection and Vaccination Study in Dialysis Patients, Solid Organ Recipients and Staff","status":"UNKNOWN","sponsor":"Technische Universität Dresden","startDate":"2021-01-15","conditions":"SARS-CoV-2 Infection, Active Immunization, Immune Response","enrollment":3500},{"nctId":"NCT05470803","phase":"PHASE3","title":"An Observer-blind, Cohort Randomized, Exploratory Phase 3 Study to Evaluate the Safety and Immunogenicity of Recombinant Covid-19 Vaccine, mRNA Covid-19 Vaccine and Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine as 4th Dose in Individuals Primed/ Boosted With Various Regimens","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2022-08","conditions":"COVID-19","enrollment":360},{"nctId":"NCT05124171","phase":"PHASE3","title":"Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-12-08","conditions":"COVID-19, Vaccine Reaction","enrollment":247},{"nctId":"NCT05438472","phase":"","title":"Incidence, Patient Characteristics and Outcome of Myocarditis After COVID-19 mRNA Vaccine","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-12-10","conditions":"Myocarditis","enrollment":835},{"nctId":"NCT05396573","phase":"PHASE1","title":"A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19","status":"UNKNOWN","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2022-07","conditions":"COVID-19","enrollment":120},{"nctId":"NCT05124483","phase":"PHASE2","title":"Anti-COVID19 VaccinaTion AKS-452 BOOSTER (ACT-BOOSTER Study)","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2022-04-21","conditions":"COVID-19","enrollment":600},{"nctId":"NCT04951323","phase":"PHASE3","title":"Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)","status":"UNKNOWN","sponsor":"University of Liege","startDate":"2021-03-22","conditions":"Coronavirus Disease 2019 (Covid19), Hematopoietic Neoplasms","enrollment":50},{"nctId":"NCT05378191","phase":"PHASE2","title":"Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose","status":"UNKNOWN","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2021-04-22","conditions":"Covid19","enrollment":600},{"nctId":"NCT05029245","phase":"PHASE3","title":"IntraDermal Versus Intramuscular Comirnaty® Efficacy Study","status":"WITHDRAWN","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2021-08-31","conditions":"Covid19 Vaccine, Covid19","enrollment":""},{"nctId":"NCT05329064","phase":"PHASE4","title":"Determining Reactogenicity and Immunogenicity of Delayed COVID-19 Vaccine Schedule in Children","status":"UNKNOWN","sponsor":"KK Women's and Children's Hospital","startDate":"2022-03-24","conditions":"Vaccine Reaction, COVID-19, Children, Only","enrollment":150},{"nctId":"NCT05329051","phase":"PHASE2","title":"A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-07-01","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":400},{"nctId":"NCT05239806","phase":"PHASE2","title":"A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-04-01","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":400},{"nctId":"NCT04834869","phase":"","title":"COVID-19 Vaccines Safety Tracking (CoVaST)","status":"RECRUITING","sponsor":"Masaryk University","startDate":"2021-04-01","conditions":"Adverse Reaction to Vaccine, COVID19 Vaccine","enrollment":30000},{"nctId":"NCT05095844","phase":"","title":"National Vaccine Adverse Event Reporting Survey and Etiology","status":"UNKNOWN","sponsor":"Neuroganics LLC","startDate":"2022-03-15","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine Reaction","enrollment":100000},{"nctId":"NCT05238441","phase":"PHASE2","title":"A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-03-20","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":360},{"nctId":"NCT05238454","phase":"PHASE2","title":"A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-03-20","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":600},{"nctId":"NCT05145348","phase":"","title":"Prospective Monitoring of Antibody Response Following COVID-19 Vaccination in Patients With Down Syndrome.","status":"UNKNOWN","sponsor":"UMC Utrecht","startDate":"2021-02-03","conditions":"Down Syndrome, SARS-CoV-2 Vaccination","enrollment":640},{"nctId":"NCT04569383","phase":"PHASE1","title":"Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2020-10-05","conditions":"Covid19","enrollment":30},{"nctId":"NCT04907331","phase":"PHASE2","title":"Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2","status":"UNKNOWN","sponsor":"Medical University Innsbruck","startDate":"2021-05-10","conditions":"SARS-CoV2 Infection","enrollment":3000},{"nctId":"NCT04900467","phase":"NA","title":"Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-05-28","conditions":"Adult Who Received a First Dose of an mRNA Vaccine (Pfizer-BioNTech or Moderna) and Need to Receive a Second Dose","enrollment":418},{"nctId":"NCT04769258","phase":"","title":"Effectiveness and Safety of COVID-19 Vaccine in Patients With IBD Treated With Immunomodulatory or Biological Drugs (ESCAPE-IBD)","status":"UNKNOWN","sponsor":"Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)","startDate":"2021-03-01","conditions":"Inflammatory Bowel Diseases","enrollment":1380}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":106,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comirnaty Vaccine","genericName":"Comirnaty Vaccine","companyName":"Clover Biopharmaceuticals AUS Pty","companyId":"clover-biopharmaceuticals-aus-pty","modality":"Biologic","firstApprovalDate":"","aiSummary":"Comirnaty is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection. Used for Prevention of COVID-19 disease caused by SARS-CoV-2.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}